<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;HNF1B&lt;/i&gt; (renal cysts and diabetes syndrome gene)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>HNF1B</i> (renal cysts and diabetes syndrome gene)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>HNF1B</i> (renal cysts and diabetes syndrome gene)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony Bleyer, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1688877090"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline genetic testing of <em>HNF1B</em> (also called <em>TCF2</em>). The resulting disorder has been called renal cysts and diabetes syndrome, although some individuals with <em>HNF1B</em> syndromes have neither renal cysts nor diabetes [<a href="#rid1">1</a>]. </p><p>Common features include  (<a class="graphic graphic_table graphicRef134647" href="/d/graphic/134647.html" rel="external">table 1</a>) (see <a class="local">'Clinical features'</a> below): </p><p class="bulletIndent1"><span class="glyph">●</span>Congenital anomalies of the kidney and urinary tract (CAKUT), especially kidney cysts</p><p class="bulletIndent1"><span class="glyph">●</span>Genitourinary tract abnormalities such as bicornuate uterus</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease (CKD)</p><p class="bulletIndent1"><span class="glyph">●</span>Maturity-onset diabetes of the young</p><p class="bulletIndent1"><span class="glyph">●</span>Hypomagnesemia and hyperuricemia</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated liver function tests (LFTs)</p><p></p><p>The rarity of this condition, variable penetrance (see <a class="local">'Inheritance'</a> below), high proportion of de novo pathogenic variants, and lack of specificity of some of the clinical findings can make this condition difficult to diagnose.</p><p class="headingAnchor" id="H2580320290"><span class="h2"><i>HNF1B </i>gene</span><span class="headingEndMark"> — </span><em>HNF1B</em> encodes hepatocyte nuclear factor 1 beta, a transcription factor that regulates development and mitochondrial function and is expressed in the kidney, pancreas, liver, and reproductive system. Heterozygous variants in <em>HNF1B</em> result in a syndrome affecting these organs; inheritance is autosomal dominant.</p><p>This syndrome can also occur in individuals with a deletion involving 1.4 megabases of chromosome 17 (17q12 deletion syndrome), which includes <em>HNF1B</em> and approximately 14 other genes. This deletion also causes neurodevelopmental and neuropsychiatric manifestations, including intellectual disability, autism spectrum disorder, schizophrenia, and bipolar disorder [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '17q12 deletion syndrome'</a>.)</p><p class="headingAnchor" id="H3443322275"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>Confirm that the result applies to the tested individual and determine whether testing was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory) or if testing should be repeated in a certified laboratory. These and other caveats are summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H3790913955"><span class="h2">Interpretation of variants</span><span class="headingEndMark"> — </span>Gene variants are classified according to the confidence that they are disease-causing (pathogenic) versus benign polymorphisms  (<a class="graphic graphic_table graphicRef122646" href="/d/graphic/122646.html" rel="external">table 3</a>). Pathogenicity refers to the link between the variant and the disease, not the likelihood that disease will occur. Some individuals with a pathogenic variant may have other characteristics that protect them from developing disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenic variants in <em>HNF1B</em> include gene deletions, truncations, and missense variants that result in amino acid substitutions [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variants that are clearly not associated with disease may be reported as negative, benign, or likely benign. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variants of undetermined significance (VUS) may result in an amino acid substitution not previously associated with disease. A VUS can be reclassified when it is found to be pathogenic or benign.</p><p></p><p class="bulletIndent1">When evaluating a VUS, the clinician must consider whether clinical findings are consistent with effects mediated by impaired <em>HNF1B </em>function. This often requires communication between a geneticist, genetic counselor, nephrologist, endocrinologist, and/or <em>HNF1B </em>expert. An extensive family history should be obtained that includes at least three generations, if possible, and genetic testing should be considered in affected and unaffected relatives to determine the correlation of the variant with clinical findings. Evaluation of family members for unique findings (bicornuate uterus, maturity-onset diabetes of youth, hypomagnesemia, hyperuricemia, elevated LFTs), may help determine the likelihood that the variant is pathogenic. Nonspecific findings such as CKD may result from other conditions and are less helpful.</p><p></p><p>Diagnostic challenges include incomplete penetrance (likelihood of manifesting disease), variable expressivity (constellation of clinical findings), and variable disease severity, with some individuals developing end-stage kidney disease (ESKD) when young and others having mild CKD. </p><p>Considerations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Was testing performed for a condition associated with <em>HNF1B</em> variants?</p><p class="bulletIndent1"><span class="glyph">●</span>Were variants identified in other genes that better explain the clinical findings?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the <em>HNF1B</em> variant track with clinical findings in relatives? </p><p class="bulletIndent1"><span class="glyph">●</span>Are there other symptoms not explained by the <em>HNF1B</em> variant that are better explained by a pathogenic variant in a different gene?</p><p></p><p class="headingAnchor" id="H4204180821"><span class="h2">Inheritance</span><span class="headingEndMark"> — </span>Inheritance is autosomal dominant, with a 50 percent risk of transmission from affected parent to a child  (<a class="graphic graphic_algorithm graphicRef134754" href="/d/graphic/134754.html" rel="external">algorithm 1</a>). A pathogenic variant in<em> HNF1B</em> need only be present at one allele (heterozygous) to cause clinical findings.</p><p>A negative family history cannot be used to exclude the possibility of a germline <em>HNF1B</em> variant, since approximately 30 to 50 percent of <em>HNF1B</em> variants occur de novo rather than being inherited [<a href="#rid4">4</a>].</p><p>Penetrance is incomplete (affected individuals may have all, some, or none of the findings), and expression is variable, with disparate phenotypes within the same family. (See  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Penetrance and expressivity'</a>.)</p><p class="headingAnchor" id="H1098991220"><span class="h1">IMPLICATIONS FOR THE TESTED INDIVIDUAL</span></p><p class="headingAnchor" id="H639242099"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Disease penetrance and expressivity (presence of individual clinical characteristics) is highly variable within families, which can make diagnosis difficult. For example, hyperechogenic kidneys may have been identified in utero in the index case; the patient's mother may have a single kidney, and a sibling may have gout, chronic kidney disease (CKD), and hypomagnesemia.</p><p>Individuals with pathogenic variants in <em>HNF1B </em>can develop a number of clinical manifestations [<a href="#rid5">5-7</a>]. Examples include  (<a class="graphic graphic_table graphicRef134647" href="/d/graphic/134647.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital anomalies of the kidney and urinary tract (CAKUT)</strong> – The most common CAKUT manifestation is bilateral kidney cysts [<a href="#rid8">8</a>]. Other manifestations include solitary kidney, hypoplastic kidneys, horseshoe kidney, dilation of the upper urinary tract, or dysplastic kidneys (identified as hyperechogenic kidneys on prenatal ultrasound). Pediatric cases are often identified by screening neonatal ultrasound, often showing bilateral hyperechogenic kidneys [<a href="#rid9">9</a>]. Pathogenic variants in <em>HNF1B</em> account for 5 percent to 31 percent of cases of CAKUT depending on the phenotypic selection of the cohort [<a href="#rid10">10,11</a>]. Genitourinary abnormalities are more frequent in females and include bicornuate uterus, uterus didelphys, absent uterus, double vagina, and vaginal hypoplasia [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD with a bland urinary sediment</strong> – Loss of kidney function usually occurs gradually, with a glomerular filtration rate (GFR) decline of approximately 1 mL/min annually in one pediatric cohort; a more rapid GFR decline is associated with an increasing number of kidney cysts [<a href="#rid9">9</a>]. CKD may present at any age, and the rate of progression is highly variable. In one cohort of 24 affected adults, CKD occurred in 92 percent, at a median age of 35 years, with progression to end-stage kidney disease (ESKD) in four, acute unexplained worsening in three, and a median estimated GFR (eGFR) decline of 2.45 mL/min/1.73 m<sup>2</sup>/year [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course"</a> and  <a class="medical medical_review" href="/d/html/102837.html" rel="external">"Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maturity-onset diabetes of the young (MODY) </strong>– <em>HNF1B </em>pathogenic variants or deletions can cause MODY type 5, which occurs in approximately one-third of adults with <em>HNF1B</em> variants [<a href="#rid13">13</a>]. Progressive loss of beta cell function often occurs. Impaired glucose tolerance is rarely observed in childhood. Pancreatic hypoplasia with subclinical pancreatic dysfunction has been reported in several individuals [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomagnesemia and hyperuricemia </strong>– A low serum magnesium due to decreased magnesium reabsorption in the kidney occurs in approximately 40 percent of children and 63 percent of adults [<a href="#rid15">15</a>]. It may be severe enough to prolong the QTc interval; one report described hypocalcemia and tetany [<a href="#rid15">15</a>]. Reduced uric acid excretion is responsible for hyperuricemia in 37 percent of children with an early onset at a median age of one year. It can occur by early adulthood and can cause gout [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased liver function tests (LFTs)</strong> – Mild LFT elevation (transaminases and alkaline phosphatase) is the most frequent hepatic finding; liver ultrasound and biopsy (generally not indicated) are normal [<a href="#rid7">7</a>]. Biliary cysts may be present [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/651.html" rel="external">"Biliary cysts"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– Other clinical features reported in patients with <em>HNF1B</em> variants include hyperparathyroidism and hearing loss [<a href="#rid18">18</a>].</p><p></p><p>Individuals with 17q12 deletion syndrome often have neurodevelopmental and neuropsychiatric disorders (intellectual disability, autism spectrum disorder, schizophrenia, bipolar disorder, speech and motor delay), in addition to findings from loss of <em>HNF1B</em> function [<a href="#rid2">2,19</a>]. (See  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '17q12 deletion syndrome'</a>.)</p><p class="headingAnchor" id="H3402244060"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Individuals with a pathogenic variant in <em>HNF1B</em> should undergo the following initial testing if not done already:</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging for kidney cysts, reflux, or other abnormalities. Uterine imaging may be considered for females when age-appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comprehensive metabolic panel, including LFTs</p><p class="bulletIndent2"><span class="glyph">•</span>Serum urate</p><p class="bulletIndent2"><span class="glyph">•</span>Hemoglobin A1C, fasting glucose</p><p class="bulletIndent2"><span class="glyph">•</span>Serum magnesium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If hypomagnesemia is present, electrocardiogram to assess QTc interval. </p><p></p><p class="headingAnchor" id="H1805036263"><span class="h2">Management</span></p><p class="headingAnchor" id="H600682847"><span class="h3">Interventions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CAKUT</strong> – Individuals with cystic kidneys or other anatomic urinary tract changes should be referred to a urologist and nephrologist (or pediatric nephrologist, depending on age). Cysts are overwhelmingly likely to be benign, especially in childhood, but annual monitoring with kidney ultrasound should be considered. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1">Genitourinary tract abnormalities should be evaluated by a urologist or gynecologist. (See  <a class="medical medical_review" href="/d/html/6106.html" rel="external">"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD</strong> – No specific interventions are available. The value of common interventions for CKD is unknown (angiotensin-converting enzyme [ACE] inhibitors, angiotensin II receptor blockers [ARBs], sodium-glucose transporter 2 [SGLT-2] inhibitors). Management is similar to the general population, including treatment of hypertension and avoidance of nephrotoxic medications. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MODY</strong> – Oral hypoglycemic therapy may be required initially, although most patients will eventually require insulin due to decreasing insulin production [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomagnesemia and hyperuricemia</strong> – Hypomagnesemia is difficult to treat due to rapid excretion. Frequent administration may be most effective. Mild hypomagnesemia likely does not require therapy, especially if the QTc interval is normal. (See  <a class="medical medical_review" href="/d/html/834.html" rel="external">"Hypomagnesemia: Evaluation and treatment"</a>.)</p><p></p><p class="bulletIndent1">Asymptomatic hyperuricemia does not require intervention, but <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> is indicated for gout, especially in younger individuals, who are prone to worsening and tophus development if untreated. Allopurinol-allergic individuals can receive <a class="drug drug_general" data-topicid="9079" href="/d/drug information/9079.html" rel="external">febuxostat</a>. (See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LFTs</strong> – Mildly elevated LFTs do not require intervention. </p><p></p><p class="headingAnchor" id="H934247113"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Annual monitoring includes  (<a class="graphic graphic_table graphicRef134647" href="/d/graphic/134647.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive metabolic panel with GFR estimation</p><p class="bulletIndent1"><span class="glyph">●</span>Serum magnesium</p><p class="bulletIndent1"><span class="glyph">●</span>Uric acid</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin A1C</p><p class="bulletIndent1"><span class="glyph">●</span>LFTs </p><p class="bulletIndent1"><span class="glyph">●</span>Kidney ultrasound, if cysts develop</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of development as appropriate</p><p></p><p>Testing frequency can be increased if abnormalities develop or worsen.</p><p class="headingAnchor" id="H635300296"><span class="h1">FIRST-DEGREE RELATIVES</span><span class="headingEndMark"> — </span>A major benefit of identifying a pathogenic variant in <em>HNF1B</em> is avoiding extensive diagnostic evaluations that may confer risks and costs in the tested individual and their first-degree relatives [<a href="#rid3">3</a>].</p><p>Parents of the affected individual should be tested, even if asymptomatic, to determine if the <em>HNF1B</em> variant was inherited or occurred de novo  (<a class="graphic graphic_algorithm graphicRef134754" href="/d/graphic/134754.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>If the variant is present in a parent, siblings of the affected individual and siblings of the parent should receive counseling regarding risks and benefits of genetic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the variant occurred de novo, testing of other family members is generally not indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regardless of whether the variant is inherited or de novo, the individual's children should be tested, and, if positive, associated treatable abnormalities should be evaluated. The timing of <em>HNF1B</em> genetic testing in children should be made in conjunction with a genetic counselor or pediatric geneticist. Testing of children is appropriate because of the need to evaluate and monitor for treatable conditions such as vesicoureteral reflux, hypomagnesemia, and diabetes.</p><p></p><p class="headingAnchor" id="H1136835806"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H1341813420"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney cysts</strong> – (See  <a class="medical medical_review" href="/d/html/1685.html" rel="external">"Autosomal dominant tubulointerstitial kidney disease"</a> and  <a class="medical medical_review" href="/d/html/6144.html" rel="external">"Kidney cystic diseases in children", section on 'Genetic disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CAKUT</strong> – (See  <a class="medical medical_review" href="/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a> and  <a class="medical medical_review" href="/d/html/6106.html" rel="external">"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MODY</strong> – (See  <a class="medical medical_review" href="/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes"</a> and  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H1874112135"><span class="h2">Locating an expert</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical geneticists</strong> – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=132181" target="_blank">ACMG</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counselors</strong> – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=132181" target="_blank">NSGC</a>). Genetic testing laboratories may also provide virtual (online or telephone) access to a genetic counselor. </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li class="breakAll">Mitchel MW, Moreno-De-Luca D, Myers SM, et al. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.</li><li><a class="nounderline abstract_t">Bleyer AJ, Kmoch S. The Varied Clinical Presentation of Autosomal Dominant Tubulointerstitial Kidney Disease Due to HNF1β Mutations. Kidney Int Rep 2020; 5:2133.</a></li><li><a class="nounderline abstract_t">Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int 2011; 80:768.</a></li><li><a class="nounderline abstract_t">Piedrafita A, Balayssac S, Casemayou A, et al. Hepatocyte nuclear factor-1β shapes the energetic homeostasis of kidney tubule cells. FASEB J 2021; 35:e21931.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, Jaureguiberry G. HNF1B-associated clinical phenotypes: the kidney and beyond. Pediatr Nephrol 2016; 31:707.</a></li><li><a class="nounderline abstract_t">Bleyer AJ, Wolf MT, Kidd KO, et al. Autosomal dominant tubulointerstitial kidney disease: more than just HNF1β. Pediatr Nephrol 2022; 37:933.</a></li><li><a class="nounderline abstract_t">Raaijmakers A, Corveleyn A, Devriendt K, et al. Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. Nephrol Dial Transplant 2015; 30:835.</a></li><li><a class="nounderline abstract_t">Okorn C, Goertz A, Vester U, et al. HNF1B nephropathy has a slow-progressive phenotype in childhood-with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry. Pediatr Nephrol 2019; 34:1065.</a></li><li><a class="nounderline abstract_t">Heidet L, Decramer S, Pawtowski A, et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin J Am Soc Nephrol 2010; 5:1079.</a></li><li><a class="nounderline abstract_t">Clissold RL, Hamilton AJ, Hattersley AT, et al. HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum. Nat Rev Nephrol 2015; 11:102.</a></li><li><a class="nounderline abstract_t">Oram RA, Edghill EL, Blackman J, et al. Mutations in the hepatocyte nuclear factor-1β (HNF1B) gene are common with combined uterine and renal malformations but are not found with isolated uterine malformations. Am J Obstet Gynecol 2010; 203:364.e1.</a></li><li><a class="nounderline abstract_t">Nagano C, Morisada N, Nozu K, et al. Clinical characteristics of HNF1B-related disorders in a Japanese population. Clin Exp Nephrol 2019; 23:1119.</a></li><li><a class="nounderline abstract_t">Bellanné-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 2004; 140:510.</a></li><li><a class="nounderline abstract_t">Adalat S, Woolf AS, Johnstone KA, et al. HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 2009; 20:1123.</a></li><li><a class="nounderline abstract_t">Verhave JC, Bech AP, Wetzels JF, Nijenhuis T. Hepatocyte Nuclear Factor 1β-Associated Kidney Disease: More than Renal Cysts and Diabetes. J Am Soc Nephrol 2016; 27:345.</a></li><li><a class="nounderline abstract_t">Kettunen JLT, Parviainen H, Miettinen PJ, et al. Biliary Anomalies in Patients With HNF1B Diabetes. J Clin Endocrinol Metab 2017; 102:2075.</a></li><li><a class="nounderline abstract_t">Ferrè S, Bongers EM, Sonneveld R, et al. Early development of hyperparathyroidism due to loss of PTH transcriptional repression in patients with HNF1β mutations? J Clin Endocrinol Metab 2013; 98:4089.</a></li><li><a class="nounderline abstract_t">Laliève F, Decramer S, Heidet L, et al. School level of children carrying a HNF1B variant or a deletion. Eur J Hum Genet 2020; 28:56.</a></li></ol></div><div id="topicVersionRevision">Topic 132181 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mitchel MW, Moreno-De-Luca D, Myers SM, et al. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33306044" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Varied Clinical Presentation of Autosomal Dominant Tubulointerstitial Kidney Disease Due to HNF1βMutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21775974" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34653285" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatocyte nuclear factor-1βshapes the energetic homeostasis of kidney tubule cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160100" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : HNF1B-associated clinical phenotypes: the kidney and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34021396" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autosomal dominant tubulointerstitial kidney disease: more than just HNF1β.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25500806" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30666461" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : HNF1B nephropathy has a slow-progressive phenotype in childhood-with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378641" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536396" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633866" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mutations in the hepatocyte nuclear factor-1β(HNF1B) gene are common with combined uterine and renal malformations but are not found with isolated uterine malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31131422" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical characteristics of HNF1B-related disorders in a Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068978" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389850" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : HNF1B mutations associate with hypomagnesemia and renal magnesium wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26319241" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatocyte Nuclear Factor 1β-Associated Kidney Disease: More than Renal Cysts and Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324003" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biliary Anomalies in Patients With HNF1B Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979948" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early development of hyperparathyroidism due to loss of PTH transcriptional repression in patients with HNF1βmutations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31481685" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : School level of children carrying a HNF1B variant or a deletion.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
